Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD

Blood

Volumn 126, Issue 4, 2015, Pages 437-444

  Chopra, Martin ^a,b   Brandl, Andreas ^a,b   Siegmund, Daniela ^a   Mottok, Anja ^c   Schäfer, Viktoria ^a   Biehl, Marlene ^a,b   Kraus, Sabrina ^a,b,d   Bäuerlein, Carina A ^a,b   Ritz, Miriam ^a,b   Mattenheimer, Katharina ^a,b   Schwinn, Stefanie ^a,b   Seher, Axel ^a   Grabinger, Thomas ^e   Einsele, Hermann ^a   Rosenwald, Andreas ^c   Brunner, Thomas ^e   Beilhack, Andreas ^a,b,d   Wajant, Harald ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d Else Kröner Forschungskolleg Würzburg   (Germany)

^e UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; CYTOKINE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR INDUCIBLE 14; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 18D1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; FC RECEPTOR; FCGR1 PROTEIN, MOUSE; IMMUNOGLOBULIN G; MESSENGER RNA; RITUXIMAB; TNFSF12 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; INFLAMMATORY BOWEL DISEASE; INTESTINE CELL; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECIPIENT; T LYMPHOCYTE; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; INTESTINE; LUMINESCENCE; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; APOPTOSIS; BLOTTING, WESTERN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; INTESTINES; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, IGG; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RITUXIMAB; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 84937773001     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-620583     Document Type: Article

References (54)

1. Chicheportiche Y, Bourdon PR, Xu H, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem. 1997;272(51):32401-32410.
2. Wiley SR, Cassiano L, Lofton T, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 2001;15(5):837-846.
3. Meighan-Mantha RL, Hsu DK, Guo Y, et al. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem. 1999; 274(46):33166-33176.
4. Donohue PJ, Richards CM, Brown SA, et al. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol. 2003;23(4):594-600.
5. Ebihara N, Nakayama M, Tokura T, Ushio H, Murakami A. Expression and function of fibroblast growth factor-inducible 14 in human corneal myofibroblasts. Exp Eye Res. 2009;89(2):256-262.
6. Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T. Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin Exp Immunol. 2006;146(3):540-549.
7. Sanz AB, Sanchez-Niño MD, Carrasco S, et al. Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells. PLoS ONE. 2012;7(10):e47440.
8. Whitsett TG, Cheng E, Inge L, et al. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol. 2012;181(1):111-120.
9. Burkly LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev. 2011;244(1):99-114.
10. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology, and therapeutic targeting. Nat Rev Drug Discov. 2008;7(5):411-425.
11. Vince JE, Silke J. TWEAK shall inherit the earth. Cell Death Differ. 2006;13(11):1842-1844.
12. Girgenrath M, Weng S, Kostek CA, et al. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J. 2006;25(24):5826-5839.
13. Karaca G, Swiderska-Syn M, Xie G, et al. TWEAK/Fn14 signaling is required for liver regeneration after partial hepatectomy in mice. PLoS ONE. 2014;9(1):e83987.
14. Wu F, Guo L, Jakubowski A, et al. TNF-like weak inducer of apoptosis (TWEAK) promotes beta cell neogenesis from pancreatic ductal epithelium in adult mice. PLoS ONE. 2013;8(8):e72132.
15. Tirnitz-Parker JE, Olynyk JK, Ramm GA. Role of TWEAK in coregulating liver progenitor cell and fibrogenic responses. Hepatology. 2014;59(3):1198-1201.
16. Mittal A, Bhatnagar S, Kumar A, et al. The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J Cell Biol. 2010;188(6):833-849.
17. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139-170.
18. Li HW, Sykes M. Emerging concepts in haematopoietic cell transplantation. Nat Rev Immunol. 2012;12(6):403-416.
19. Dohi T, Borodovsky A, Wu P, et al. TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. Gastroenterology. 2009;136(3):912-923.
20. Son A, Oshio T, Kawamura YI, et al. TWEAK/ Fn14 pathway promotes a T helper 2-type chronic colitis with fibrosis in mice. Mucosal Immunol. 2013;6(6):1131-1142.
21. Kawashima R, Kawamura YI, Oshio T, et al. Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis. Gastroenterology. 2011;141(6):2119-2129, e8.
22. Trebing J, Lang I, Chopra M, et al. A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo. MAbs. 2014;6(1):297-308.
23. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versushost disease reveal sequential infiltration of T-cell subsets. Blood. 2005;106(3):1113-1122.
24. Bäuerlein CA, Riedel SS, Baker J, et al. A diagnostic window for the treatment of acute graftversus-host disease prior to visible clinical symptoms in a murine model. BMC Med. 2013;11: 134.
25. Chopra M, Kraus S, Schwinn S, et al. Noninvasive bioluminescence imaging to monitor the immunological control of a plasmablastic lymphoma-like B cell neoplasia after hematopoietic cell transplantation. PLoS ONE. 2013;8(12):e81320.
26. Edinger M, Hoffmann P, Ermann J, et al. CD4+ CD25+ regulatory T cells preserve graft-versustumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144-1150.
27. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88(8):3230-3239.
28. Jakob S, Corazza N, Diamantis E, Kappeler A, Brunner T. Detection of apoptosis in vivo using antibodies against caspase-induced neoepitopes. Methods. 2008;44(3):255-261.
29. Schmaltz C, Alpdogan O, Muriglan SJ, et al. Donor T cell-derived TNF is required for graftversus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood. 2003;101(6):2440-2445.
30. Levine JE. Implications of TNF-α in the pathogenesis and management of GVHD. Int J Hematol. 2011;93(5):571-577.
31. Piguet PF, Vesin C, Guo J, Donati Y, Barazzone C. TNF-induced enterocyte apoptosis in mice is mediated by the TNF receptor 1 and does not require p53. Eur J Immunol. 1998;28(11):3499-3505.
32. Inagaki-Ohara K, Yada S, Takamura N, et al. p53-dependent radiation-induced crypt intestinal epithelial cells apoptosis is mediated in part through TNF-TNFR1 system. Oncogene. 2001;20(7):812-818.
33. Marini M, Bamias G, Rivera-Nieves J, et al. TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc Natl Acad Sci USA. 2003;100(14):8366-8371.
34. Goretsky T, Dirisina R, Sinh P, et al. p53 mediates TNF-induced epithelial cell apoptosis in IBD. Am J Pathol. 2012;181(4):1306-1315.
35. Günther C, Martini E, Wittkopf N, et al. Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature. 2011;477(7364):335-339.
36. Schneider P, Schwenzer R, Haas E, et al. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol. 1999;29(6):1785-1792.
37. Wicovsky A, Salzmann S, Roos C, et al. TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death Differ. 2009;16(11):1445-1459.
38. Vince JE, Chau D, Callus B, et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol. 2008;182(1):171-184.
39. Chicheportiche Y, Chicheportiche R, Sizing I, et al. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res. 2002;4(2):126-133.
40. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2002;299(3):488-493.
41. Xu H, Okamoto A, Ichikawa J, et al. TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL-8 and GM-CSF. Biochem Biophys Res Commun. 2004;318(2):422-427.
42. Jin L, Nakao A, Nakayama M, et al. Induction of RANTES by TWEAK/Fn14 interaction in human keratinocytes. J Invest Dermatol. 2004;122(5):1175-1179.
43. Salzmann S, Seher A, Trebing J, et al. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity. J Biol Chem. 2013;288(19):13455-13466.
44. Ferrara JL. Pathogenesis of acute graft-versushost disease: cytokines and cellular effectors. J Hematother Stem Cell Res. 2000;9(3):299-306.
45. Coghill JM, Sarantopoulos S, Moran TP, Murphy WJ, Blazar BR, Serody JS. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood. 2011;117(12):3268-3276.
46. Hill GR, Teshima T, Rebel VI, et al. The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity. J Immunol. 2000;164(2):656-663.
47. Brown GR, Lee E, Thiele DL. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J->C57BL/6J x bm12)F1 mice. J Immunol. 2002;168(6):3065-3071.
48. Soloviova K, Puliaiev M, Haas M, Via CS. In vivo maturation of allo-specific CD8 CTL and prevention of lupus-like graft-versus-host disease is critically dependent on T cell signaling through the TNF p75 receptor but not the TNF p55 receptor. J Immunol. 2013;190(9):4562-4572.
49. Sellar RS, Peggs KS. Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation. Future Oncol. 2012;8(12):1549-1565.
50. Wilson NS, Yang B, Yang A, et al. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell. 2011;19(1):101-113.
51. Li F, Ravetch JV. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science. 2011;333(6045):1030-1034.
52. Li F, Ravetch JV. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement. Proc Natl Acad Sci USA. 2012;109(27):10966-10971.
53. Li F, Ravetch JV. Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo. Proc Natl Acad Sci USA. 2013;110(48):19501-19506.
54. Zhao Z, Burkly LC, Campbell S, et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graftversus-host model of systemic lupus erythematosus. J Immunol. 2007;179(11):7949-7958.